Ireland - English - HPRA (Health Products Regulatory Authority)

h. lundbeck a/s - sertindole - film coated tablet - 4 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

h. lundbeck a/s - sertindole - film coated tablet - 12 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

h. lundbeck a/s - sertindole - film coated tablet - 16 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

h. lundbeck a/s - sertindole - film coated tablet - 20 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

h. lundbeck a/s - sertindole - film coated tablet - 4 milligram

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - levodopa, quantity: 125 mg; carbidopa, quantity: 31.25 mg (equivalent: carbidopa monohydrate, qty 33.8 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - levodopa, quantity: 75 mg; carbidopa, quantity: 18.75 mg (equivalent: carbidopa monohydrate, qty 20.25 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - levodopa, quantity: 200 mg; carbidopa, quantity: 50 mg (equivalent: carbidopa monohydrate, qty 54.1 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - levodopa, quantity: 150 mg; carbidopa, quantity: 37.5 mg (equivalent: carbidopa monohydrate, qty 40.5 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide; iron oxide yellow - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - levodopa, quantity: 100 mg; carbidopa, quantity: 25 mg (equivalent: carbidopa monohydrate, qty 27 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide; iron oxide yellow - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.